文献速递肺栓塞与肺血管病

美国肺动脉高压科学注册研究:基线特征

United States Pulmonary Hypertension Scientific Registry: Baseline Characteristics.
PubMed 文献 · Chest · 2020-08-26

13%检出致病或疑似致病变异,常报告减肥药、娱乐性药物及口服避孕药暴露。

要点

  • Group 1 PAH以中年女性为主,特发性/家族性及相关性PAH常见。
  • 诊断延迟仍存在,症状 onset 至诊断导管平均1.9年。
  • 基因检测可重分类部分IPAH和APAH为遗传性PAH。

核心结论

  • Group 1 PAH患者仍以中年女性为主,特发性或相关性PAH常见,诊断延迟持续存在,联合靶向治疗较前更普遍,基因检测常发现未疑及的遗传性PAH。

研究设计与样本

  • 美国15个中心连续入组确诊Group 1 PAH且5年内符合血流动力学标准的成人患者,共499例入组。

主要发现

  • 499例中特发性/家族性PAH 240例(48%),相关性PAH 256例(51%),肺静脉闭塞病/肺毛细血管瘤病3例(1%)。
  • 平均年龄55.8岁,平均BMI 29.2 kg/m2,女性占79%,症状 onset 至诊断导管平均1.9年。
  • 女性常报告流产(37%),但PAH在妊娠后6个月内诊断者仅1.9%。
  • 基因检测在13%患者中检出致病或疑似致病变异,将18% IPAH和5% APAH重分类为遗传性PAH。

临床怎么用

  • 对Group 1 PAH患者应关注诊断延迟并及早行右心导管确诊。
  • 可考虑基因检测以识别遗传性PAH并重分类。
  • 应详细采集减肥药、娱乐性药物、口服避孕药及妊娠并发症史。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The treatment, genotyping, and phenotyping of patients with World Health Organization Group 1 pulmonary arterial hypertension (PAH) have evolved dramatically in the last decade. RESEARCH QUESTION: The United States Pulmonary Hypertension Scientific Registry was established as the first US PAH patient registry to investigate genetic information, reproductive histories, and environmental exposure data in a contemporary patient population. STUDY DESIGN AND METHODS: Investigators at 15 US centers enrolled consecutively screened adults diagnosed with Group 1 PAH who had enrolled in the National Biological Sample and Data Repository for PAH (PAH Biobank) within 5 years of a cardiac catheterization demonstrating qualifying hemodynamic criteria. Exposure and reproductive histories were collected by using a structured interview and questionnaire. The biobank provided genetic data. RESULTS: Between 2015 and 2018, a total of 499 of 979 eligible patients with clinical diagnoses of idiopathic PAH (IPAH) or familial PAH (n = 240 [48%]), associated PAH (APAH; n = 256 [51%]), or pulmonary venoocclusive disease/pulmonary capillary hemangiomatosis (n = 3 [1%]) enrolled. The mean age was 55.8 years, average BMI was 29.2 kg/m2, and 79% were women. Mean duration between symptom onset and diagnostic catheterization was 1.9 years. Sixty-six percent of patients were treated with more than one PAH medication at enrollment. Past use of prescription weight loss drugs (16%), recreational drugs (27%), and oral contraceptive pills (77%) was common. Women often reported miscarriage (37%), although PAH was rarely diagnosed within 6 months of pregnancy (1.9%). Results of genetic testing identified pathogenic or suspected pathogenic variants in 13% of patients, reclassifying 18% of IPAH patients and 5% of APAH patients to heritable PAH. INTERPRETATION: Patients with Group 1 PAH remain predominately middle-aged women diagnosed with IPAH or APAH. Delays in diagnosis of PAH persist. Treatment with combinations of PAH-targeted medications is more common than in the past. Women often report pregnancy complications, as well as exposure to anorexigens, oral contraceptives, and/or recreational drugs. Results of genetic tests frequently identify unsuspected heritable PAH.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Badlam JB, Badesch DB, Austin ED, et al. United States Pulmonary Hypertension Scientific Registry: Baseline Characteristics. Chest. 2020. PMID: 32858008. doi:10.1016/j.chest.2020.07.088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。